NGM·Healthcare·$526M·#235 / 520 in Healthcare
AQST Aquestive Therapeutics, Inc.
47SPECULATIVE
CATEGORY BREAKDOWN
GROWTH0
QUALITY50
STABILITY93
VALUATION39
GOVERNANCE20
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-22.6%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
58.3%
83
> 50% strong
Cash Runway
Months of cash at current burn rate
28 months
90
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-126.2%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
11.8x
39
< 3x strong
Rule of 40
Growth rate plus operating margin
-182
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
3.5%
28
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+25.1%
5
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE AQST WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when AQST's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.